triazoles has been researched along with Malaria, Vivax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andenmatten, N; Araeipour, N; Arch, RH; Baker, M; Bath, J; Casapia, M; Chuquiyauri, R; Cowell, AN; Duparc, S; Fidock, DA; Gobeau, N; Hinojosa, JC; Hooft van Huijsduijnen, R; Kerr, N; Llanos-Cuentas, A; Möhrle, JJ; Ng, CL; Phillips, MA; Rosario, M; Rozenberg, FD; Rückle, T; Toovey, S; Winzeler, EA | 1 |
| Bélard, S; Ramharter, M | 1 |
1 trial(s) available for triazoles and Malaria, Vivax
| Article | Year |
|---|---|
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
Topics: Adult; Antimalarials; Cohort Studies; Dihydroorotate Dehydrogenase; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Oxidoreductases Acting on CH-CH Group Donors; Peru; Plasmodium falciparum; Pyrimidines; Triazoles | 2018 |
1 other study(ies) available for triazoles and Malaria, Vivax
| Article | Year |
|---|---|
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria.
Topics: Antimalarials; Dihydroorotate Dehydrogenase; Humans; Malaria, Falciparum; Malaria, Vivax; Oxidoreductases Acting on CH-CH Group Donors; Plasmodium falciparum; Pyrimidines; Triazoles | 2018 |